The partnership aims to enhance access to clinical trials for patients suffering from pancreatic cancer by leveraging myTomorrows’ extensive database of ongoing trials.
Pancreatic cancer is notoriously challenging to treat, with a life expectancy of only 6-12 months at the time of diagnosis and a five-year survival rate of just 10%. The disease is difficult to diagnose early, often resistant to conventional treatments like chemotherapy and radiation, and has limited treatment options available.
Given these challenges, the company emphasized the importance of ensuring that patients, caregivers, and healthcare professionals are well-informed about all potential treatment avenues, including clinical trials.
The partnership will facilitate easier access to trial information through a new clinical trial search tool that will be featured on the Pancreatic Cancer Europe website. This tool will simplify the process of finding relevant clinical trials from the myTomorrows database, making it easier for patients and healthcare providers to navigate potential treatment options. The company’s expert patient navigators will also be available to assist in understanding and accessing these trials, offering support to patients and their families throughout the process.
Pancreatic cancer awareness
“We are very excited to be partnering with Pancreatic Cancer Europe, an organisation that works tirelessly to raise awareness of pancreatic cancer, promote advancements in treatments, and empower European member organisations to better address the relevant issues regarding the disease,” said Dr Michel van Harten, CEO of myTomorrows.
“Collaborating with leading patient advocacy groups like PCE helps us extend our reach to more patients in need and empower them to navigate their treatment journeys with more confidence and knowledge, while enabling pharmaceutical companies to expand access throughout the drug development cycle.”
Pancreatic Cancer Europe expressed similar optimism about the partnership. “This new partnership is an important step in the persistent fight against pancreatic cancer,” said Professor Alfredo Carrato, chair of Pancreatic Cancer Europe.
“The innovative myTomorrows platform will support patients suffering from pancreatic cancer, their caregivers, and their treating physicians by significantly easing the process of accessing and navigating clinical trials, another opportunity for them, enabling a more informed and proactive approach to treatment of this devastating disease.”
The collaboration between myTomorrows and Pancreatic Cancer Europe represents a concerted effort to address the critical need for accessible and accurate information about treatment options for pancreatic cancer patients, potentially offering new hope in the fight against this aggressive disease.